Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04588077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jul 1, 2024 to Dec 1, 2028v4
  2. Primary and study completion dates: Jul 1, 2023 to Jul 1, 2024v3
  3. Primary and study completion dates: Jul 1, 2021 to Jul 1, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Trial Details
NCT Number NCT04588077
Lead Sponsor Mercy Medical Center
Conditions Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov